Spleen and Bruton's tyrosine kinase inhibitors for the management of adult immune thrombocytopenia: A systematic review and meta-analysis of randomized controlled trials.

The subgroup analysis revealed a lower RR for serious AEs among BTK inhibitors (OR 0.78; 95%CI: 0.33 – 1.81, p=0.56, random-effect model) compared to SYK inhibitors (OR 0.90; 95%CI: 0.56 – 1.44, p=0.65, I 2 = 0%, random-effect model), but both findings still did not reach statistical significance ( Table 3 ).

also in 111,027 other papers